|Adult ADHD Home||Succeed at Work||ADHD Self Test|
|Love & Friendships||Manage Time & Money||ADHD Adult Blogs|
|The Organized Life||Stress, Sleep, Health||Adult Support Groups|
|Apps & Gadgets||Inspirational Stories||Expert Answers|
|ADHD Parenting Home||Schedules & Time||Sample Routines|
|Discipline & Behavior||Teens & Young Adults||Parent Support Group|
|ADHD Parenting Skills||Nutrition & Diet||Parenting Blogs|
|Friendships & Social Skills||Sports & Hobbies||Summer & Camps|
|ADHD Treatment Home||ADHD Medications||Medication Reviews||Adderall|
|Treating Your Child||Nutrition & Diet||Fish Oil Printable||Daytrana|
|Expert Q&As||Non-Medical Treatment||Find Professionals||Strattera|
|Behavior Therapy||Brain Training||Quillivant XR||Vyvanse|
|ADHD/LD School Home||High School & College||Accommodations|
|IEPs & 504s||ADHD Study Skills||ADHD School Guide|
|Working with School||School Organization Help||College Survival Guide|
|Social Skills at School||For Teachers Only||Is it LD? A Self Test|
|ADHD Diagnosis Home||ADHD & Women||Is it ADHD? Self Tests|
|Getting a Diagnosis||Is it a Related Condition?||Medical Q&As|
|ADHD Symptoms||Post Diagnosis Next Steps||Myths & Realities|
|Is it Learning Disabilities?||ADHD Treatment||ADHD Support Groups|
|Tools and Checklists|
|ADHD Topics A-Z|
|Share Your Story|
|Give a Gift|
|Buy Back Issues|
ADHD Medication Update
Useful new research findings released for several different ADHD medications.
Friday May 9th - 11:29am
Filed Under: ADHD Medication and Children, ADHD Stimulant Medications, Nonstimulant ADHD Medications
After announcing the FDA approval of their drug Vyvanse for adult use, the pharmaceutical company Shire shared research data on two of their other Attention Deficit Hyperactivity Disorder (ADHD) drugs, Daytrana and Intuniv, at the American Psychological Association (APA) conference in Washington D.C.
Researchers found Daytrana, an ADHD medication delivered through a patch applied to the skin, was safe and effective for both boys and girls between the ages of six and 12. Clinicians rated 83% of the children "improved" or "very much improved" across gender. In a trial of their new, investigational, nonstimulant drug Intuniv, Shire researchers found a significant improvement in functioning, as measured by symptom reduction, up to 24 hours after the dose was taken by study participants.
For more information, read the full press release from Shire.
Finally, pharmaceutical company Eli Lilly announced yesterday that their nonstimulant drug Strattera has been the first medication approved by the FDA for maintenance of ADHD symptoms. Their research showed that Strattera was significantly more effective than a placebo in preventing symptom relapse over time. This research, and the FDA approval, means that Strattera can be used to effectively treat symptoms over one's lifetime.
Read Eli Lilly's press release for more information.